Literature DB >> 12897099

Interactions between dialysis-related volume exposures, nutritional surrogates and mortality among ESRD patients.

Lynda Anne Szczech1, Donal N Reddan, Preston S Klassen, Joseph Coladonato, Benjamin Chua, Edmund G Lowrie, J Michael Lazarus, William F Owen.   

Abstract

BACKGROUND: Interdialytic weight gain is used as a surrogate for volume expansion in haemodialysis patients and as an indicator of non-compliance. Increased weight gain is associated with both a greater mortality risk and better nutrition indices. This analysis characterizes the association between dialysis-related volume expansion and mortality in the context of its interaction with nutritional surrogates.
METHODS: All patients receiving haemodialysis through Fresenius Medical Care-North America during 1998 were included. The percentage reduction in weight or intradialytic weight loss (IDWL%) was defined as the difference between the average of pre- and post-dialysis weights from the last 3 months of 1997 expressed as a percentage of post-dialysis weight. Associations between IDWL% and clinical and demographic variables were estimated using linear regression. The association between mortality risk and IDWL% was estimated using Cox proportional hazards regression.
RESULTS: Younger age, male gender, the presence of diabetes mellitus, decreasing cholesterol, post-dialysis weight and pre-dialysis blood pressure (systolic and pulse pressure) were associated with increased IDWL%. Increasing IDWL% was associated with increasing phosphorus, creatinine, albumin, potassium and urea reduction ratio. Increasing IDWL% was significantly associated with mortality at 1 year [hazard ratio (HR) = 1.07, P = 0.003]. Among patients with diabetes mellitus, increasing IDWL% was associated with a mortality HR of 1.03 (P = 0.02). Among patients without diabetes mellitus, increasing IDWL% was not associated with an increased mortality risk. Increasing IDWL% is associated with a greater mortality risk among patients with creatinine <7.26, which failed to remain significant for patients whose creatinine was >or=7.26 mg/dl. Increasing IDWL% is associated with a greater mortality risk among patients with greater post-dialysis weight, greater body mass index and lower serum sodium measurements.
CONCLUSIONS: This study confirms and extends the findings of the deleterious association between increasing IDWL% and mortality among patients with diabetes mellitus and among subgroups based on serum creatinine and body weight. The putative deleterious effect of dialysis-related volume expansion on mortality must be interpreted in the context of the patient's diabetic and nutritional status.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12897099     DOI: 10.1093/ndt/gfg225

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  14 in total

1.  Association of intradialytic blood pressure changes with hospitalization and mortality rates in prevalent ESRD patients.

Authors:  J K Inrig; E Z Oddone; V Hasselblad; Barbara Gillespie; U D Patel; D Reddan; R Toto; J Himmelfarb; J F Winchester; J Stivelman; R M Lindsay; L A Szczech
Journal:  Kidney Int       Date:  2007-01-10       Impact factor: 10.612

2.  Depressive symptoms and dietary adherence in patients with end-stage renal disease.

Authors:  Amani A Khalil; Susan K Frazier; Terry A Lennie; B Peter Sawaya
Journal:  J Ren Care       Date:  2011-03

3.  In-center hemodialysis six times per week versus three times per week.

Authors:  Glenn M Chertow; Nathan W Levin; Gerald J Beck; Thomas A Depner; Paul W Eggers; Jennifer J Gassman; Irina Gorodetskaya; Tom Greene; Sam James; Brett Larive; Robert M Lindsay; Ravindra L Mehta; Brent Miller; Daniel B Ornt; Sanjay Rajagopalan; Anjay Rastogi; Michael V Rocco; Brigitte Schiller; Olga Sergeyeva; Gerald Schulman; George O Ting; Mark L Unruh; Robert A Star; Alan S Kliger
Journal:  N Engl J Med       Date:  2010-11-20       Impact factor: 91.245

4.  Relationship between illness perceptions, treatment adherence, and clinical outcomes in patients on maintenance hemodialysis.

Authors:  Youngmee Kim; Lorraine S Evangelista
Journal:  Nephrol Nurs J       Date:  2010 May-Jun       Impact factor: 0.959

5.  Prognostic factors for mortality in middle-aged and older hemodialysis patients: a 5-year observational study.

Authors:  Kojiro Nagai; Motokazu Matsuura; Kenji Tsuchida; Hiro-Omi Kanayama; Toshio Doi; Jun Minakuchi
Journal:  J Artif Organs       Date:  2017-09-16       Impact factor: 1.731

6.  The End-Stage Renal Disease Adherence Questionnaire (ESRD-AQ): testing the psychometric properties in patients receiving in-center hemodialysis.

Authors:  Youngmee Kim; Lorraine S Evangelista; Linda R Phillips; Carol Pavlish; Joel D Kopple
Journal:  Nephrol Nurs J       Date:  2010 Jul-Aug       Impact factor: 0.959

7.  Low IGF-1 levels are associated with cardiovascular risk factors in haemodialysis patients.

Authors:  Abdishakur M Abdulle; Michael P T Gillett; Samra Abouchacra; Sufyan M Sabri; Mona Al Rukhaimi; Enyioma N Obineche; Jaipaul Singh
Journal:  Mol Cell Biochem       Date:  2007-03-27       Impact factor: 3.396

8.  Development and cultural adaptation of the Spanish version of the End Stage Renal Disease Adherence Questionnaire (SESRD-AQ).

Authors:  Youngmee Kim; Lorraine S Evangelista
Journal:  Nephrol Nurs J       Date:  2013 Nov-Dec       Impact factor: 0.959

9.  Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients.

Authors:  Jula K Inrig; Uptal D Patel; Barbara S Gillespie; Vic Hasselblad; Jonathan Himmelfarb; Donal Reddan; Robert M Lindsay; James F Winchester; John Stivelman; Robert Toto; Lynda A Szczech
Journal:  Am J Kidney Dis       Date:  2007-07       Impact factor: 8.860

10.  The mortality risk of overhydration in haemodialysis patients.

Authors:  Volker Wizemann; Peter Wabel; Paul Chamney; Wojciech Zaluska; Ulrich Moissl; Christiane Rode; Teresa Malecka-Masalska; Daniele Marcelli
Journal:  Nephrol Dial Transplant       Date:  2009-01-07       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.